6 years ago

Achilles Therapeutics Secures £100 Million in Series B Funding for Personalized Cancer Immunotherapy

  • Achilles Therapeutics, a UK-based biopharmaceutical company developing personalized cancer immunotherapies, raised £100 million in Series B financing

  • The round was led by RA Capital Management, with participation from Syncona Investment Management Limited, Forbion, Invus, Perceptive Advisors and Redmile Group

  • The company plans to use the funds to conduct two human proof-of-concept studies using a personalized T cell therapy approach targeting clonal neoantigens in non-small cell lung cancer and melanoma

  • The financing will also enable Achilles to continue building out its manufacturing capabilities and broaden its solid tumor pre-clinical product pipeline.

      • ProblemBiotechnology

      "Cancer treatment resistance led to significant unmet medical need in non-small cell lung cancer and melanoma"

      Solution

      "Personalized T cell therapies targeting clonal neoantigens in solid tumours using PELEUS™ bioinformatics platform"

      Covered on